JOP20220113A1 - طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم - Google Patents
طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدمInfo
- Publication number
- JOP20220113A1 JOP20220113A1 JOP/2022/0113A JOP20220113A JOP20220113A1 JO P20220113 A1 JOP20220113 A1 JO P20220113A1 JO P20220113 A JOP20220113 A JO P20220113A JO P20220113 A1 JOP20220113 A1 JO P20220113A1
- Authority
- JO
- Jordan
- Prior art keywords
- syndrome
- cls
- ips
- methods
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940720P | 2019-11-26 | 2019-11-26 | |
| US201962940735P | 2019-11-26 | 2019-11-26 | |
| PCT/US2020/062082 WO2021108447A1 (en) | 2019-11-26 | 2020-11-24 | Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220113A1 true JOP20220113A1 (ar) | 2023-01-30 |
Family
ID=76130747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0113A JOP20220113A1 (ar) | 2019-11-26 | 2020-11-24 | طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220064330A1 (https=) |
| EP (1) | EP4065165A4 (https=) |
| JP (2) | JP2023503611A (https=) |
| KR (1) | KR20220104201A (https=) |
| CN (1) | CN115335077A (https=) |
| AU (1) | AU2020391175A1 (https=) |
| BR (1) | BR112022010078A2 (https=) |
| CA (1) | CA3159152A1 (https=) |
| CL (4) | CL2022001355A1 (https=) |
| IL (1) | IL293363A (https=) |
| JO (1) | JOP20220113A1 (https=) |
| MX (1) | MX2022006334A (https=) |
| WO (1) | WO2021108447A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023108028A2 (en) | 2021-12-10 | 2023-06-15 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| CN108472347B (zh) * | 2015-11-09 | 2023-09-05 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| US10736960B2 (en) * | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| RU2018145364A (ru) * | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| EP3526249A4 (en) * | 2016-10-17 | 2020-07-01 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INJURY ASSOCIATED WITH A GRAFT |
| CA3055781A1 (en) * | 2017-03-14 | 2018-09-20 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
| TWI818919B (zh) * | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法 |
| EP3717004A4 (en) * | 2017-12-01 | 2021-12-01 | Children's Hospital Medical Center | COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE |
-
2020
- 2020-11-24 WO PCT/US2020/062082 patent/WO2021108447A1/en not_active Ceased
- 2020-11-24 US US17/103,672 patent/US20220064330A1/en not_active Abandoned
- 2020-11-24 CA CA3159152A patent/CA3159152A1/en active Pending
- 2020-11-24 BR BR112022010078A patent/BR112022010078A2/pt unknown
- 2020-11-24 CN CN202080094868.6A patent/CN115335077A/zh active Pending
- 2020-11-24 IL IL293363A patent/IL293363A/en unknown
- 2020-11-24 MX MX2022006334A patent/MX2022006334A/es unknown
- 2020-11-24 JP JP2022530672A patent/JP2023503611A/ja active Pending
- 2020-11-24 AU AU2020391175A patent/AU2020391175A1/en active Pending
- 2020-11-24 KR KR1020227020672A patent/KR20220104201A/ko active Pending
- 2020-11-24 EP EP20892727.7A patent/EP4065165A4/en active Pending
- 2020-11-24 JO JOP/2022/0113A patent/JOP20220113A1/ar unknown
-
2022
- 2022-05-24 CL CL2022001355A patent/CL2022001355A1/es unknown
-
2024
- 2024-01-12 US US18/411,789 patent/US20240218080A1/en not_active Abandoned
- 2024-05-13 CL CL2024001421A patent/CL2024001421A1/es unknown
- 2024-05-13 CL CL2024001420A patent/CL2024001420A1/es unknown
- 2024-05-13 CL CL2024001422A patent/CL2024001422A1/es unknown
-
2026
- 2026-01-05 JP JP2026000091A patent/JP2026062897A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240218080A1 (en) | 2024-07-04 |
| US20220064330A1 (en) | 2022-03-03 |
| CL2024001421A1 (es) | 2024-08-23 |
| EP4065165A4 (en) | 2024-10-16 |
| KR20220104201A (ko) | 2022-07-26 |
| MX2022006334A (es) | 2022-06-22 |
| IL293363A (en) | 2022-07-01 |
| CL2024001420A1 (es) | 2024-08-23 |
| AU2020391175A1 (en) | 2022-07-07 |
| CA3159152A1 (en) | 2021-06-03 |
| CN115335077A (zh) | 2022-11-11 |
| WO2021108447A1 (en) | 2021-06-03 |
| CL2022001355A1 (es) | 2023-05-19 |
| JP2023503611A (ja) | 2023-01-31 |
| BR112022010078A2 (pt) | 2022-12-13 |
| EP4065165A1 (en) | 2022-10-05 |
| CL2024001422A1 (es) | 2024-08-23 |
| JP2026062897A (ja) | 2026-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202407503B (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
| MY197758A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| MX2024010937A (es) | Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo. | |
| MX2021008044A (es) | Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| EA202190073A1 (ru) | Композиции и способы лечения видов гемоглобинопатии и талассемии | |
| BR112019024082A2 (pt) | Métodos de tratamento para distonia cervical | |
| JOP20220113A1 (ar) | طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم | |
| MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
| ZA202102023B (en) | Potentiation of helminth treatment |